-+ 0.00%
-+ 0.00%
-+ 0.00%

Kyoto iCAP invests about USD 1.1 million in Shinobi Therapeutics via convertible bonds

PUBT·07/16/2026 01:04:41
Listen to the news
Kyoto iCAP invests about USD 1.1 million in Shinobi Therapeutics via convertible bonds
  • Kyoto iCAP executed an additional investment of about USD 1.1 million in Shinobi Therapeutics via convertible bond-type bonds with stock acquisition rights.
  • Shinobi Therapeutics is a Kyoto University spinout developing allogeneic iPS-derived T-cell and NK-cell immunotherapies.
  • The company traces its platform to iPS-derived immune-cell research led by Kyoto University iPS Cell Research Institute professor Shin Kaneko.
  • Shinobi Therapeutics aims to start clinical trials for two lead programs in 2027 at multiple facilities centered on Kyoto University.
  • Founded in January 2023, Shinobi Therapeutics is headquartered in Delaware and led by CEO Daniel Kemp.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyoto University Innovation Capital Co Ltd published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.